Selected publications

Key publications describing our PDX models

Microfluidic formulation, cryoprotection and long-term stability of paclitaxel-loaded π electron-stabilized polymeric micelles

Mihyar R, Shalmani AA, Wildt V, Sheybanifard M, Wang A, May JN, Shahzad S, Buhl EM, Rütten S, Behrens D, Walther W, Tiboni M, Casettari L, Buyel JF, Rijcken CJF, Hennink WE, von Stillfried S,
Kiessling F, Shi Y, Metselaar JM, Lammers T, Peña Q. J Control Release
2024; Sep 23;375:614-626. doi: 10.1016/j.jconrel.2024.08.041
PMID: 39316925 (Weblink)

Head and neck squamous cell carcinoma (HNSCC) PDX models

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer.
Klinghammer K, Politz O, Eder T, Otto R, Raguse JD, Albers A, Kaufmann A, Tinhofer I, Hoffmann J, Keller U, Keilholz U.
Oncotarget. 2020 Oct 13;11(41):3688-3697.
PMID: 33110476 (Weblink)

Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
Klinghammer K, Otto R, Raguse JD, Albers AE, Tinhofer I, Fichtner I, Leser U, Keilholz U, Hoffmann J.
Int J Cancer. 2017 Sep 15;141(6):1215-1221. doi: 10.1002/ijc.30808. Epub 2017 Jun 21.
PMID: 28560858 (Weblink)

A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option.
Klinghammer K, Raguse JD, Plath T, Albers AE, Joehrens K, Zakarneh A, Brzezicha B, Wulf-Goldenberg A, Keilholz U, Hoffmann J, Fichtner I.
Int J Cancer. 2015 Jun 15;136(12):2940-8. doi: 10.1002/ijc.29344. Epub 2014 Nov 26.
PMID: 25404014 (Weblink)

Colorectal cancer (CRC) PDX models

Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data
Keil M, Conrad T, Becker M, Keilholz U, Yaspo ML, Lehrach H, Schütte M, Haybaeck J, Hoffmann J.
Cancers (Basel). 2021 Nov 30;13(23):6018. doi: 10.3390/cancers13236018.
PMID: 34885128 (Weblink)

Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D models.
Dahlmann M, Gambara G, Brzezicha B, Popp O, Pachmayr E, Wedeken L, Pflaume A, Mokritzkij M, Gül-Klein S, Brandl A, Schweiger-Eisbacher C, Mertins P, Hoffmann J, Keilholz U, Walther W, Regenbrecht C, Rau B, Stein U.
Mol Cancer. 2021 Oct 21;20(1):129. doi: 10.1186/s12943-021-01430-7.
PMID: 34670579 (Weblink)

Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.
Schütte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D, Keil M, Yildiriman R, Jandrasits C, Borodina T, Amstislavskiy V, Worth CL, Schweiger C, Liebs S, Lange M, Warnatz HJ, Butcher LM, Barrett JE, Sultan M, Wierling C, Golob-Schwarzl N, Lax S, Uranitsch S, Becker M, Welte Y, Regan JL, Silvestrov M, Kehler I, Fusi A, Kessler T, Herwig R, Landegren U, Wienke D, Nilsson M, Velasco JA, Garin-Chesa P, Reinhard C, Beck S, Schäfer R, Regenbrecht CR, Henderson D, Lange B, Haybaeck J, Keilholz U, Hoffmann J, Lehrach H, Yaspo ML.
Nat Commun. 2017 Feb 10;8:14262. doi: 10.1038/ncomms14262.
PMID: 28186126 (Weblink)

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
Rivera M, Fichtner I, Wulf-Goldenberg A, Sers C, Merk J, Patone G, Alp KM, Kanashova T, Mertins P,Hoffmann J, Stein U, Walther W. Neoplasia. 2021 Jan;23(1):21-35
PMID: 33212364 (Weblink)

Rapid eradication of colon carcinoma by Clostridium perfringens Enterotoxin suicidal gene therapy.
Pahle J, Menzel L, Niesler N, Kobelt D, Aumann J, Rivera M, Walther W.
BMC Cancer. 2017 Feb 13;17(1):129. doi: 10.1186/s12885-017-3123-x.
PMID: 28193196 (Weblink)

Non-small cell lung cancer (NSCLC) PDX models

Breaking the crosstalk of the Cellular Tumorigenic Network by low-dose combination therapy in lung cancer patient-derived xenografts.
Gürgen D, Conrad T, Becker M, Sebens S, Röcken C, Hoffmann J, Langhammer S.
Commun Biol. 2022 Jan 17;5(1):59. doi: 10.1038/s42003-022-03016-5.
PMID: 35039644 (Weblink)

Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance. 
Grasse S, Lienhard M, Frese S, Kerick M, Steinbach A, Grimm C, Hussong M, Rolff J, Becker M, Dreher F, Schirmer U, Boerno S, Ramisch A, Leschber G, Timmermann B, Grohé C, Lüders H, Vingron M, Fichtner I, Klein S, Odenthal M, Büttner R, Lehrach H, Sültmann H, Herwig R, Schweiger MR.
Genome Med 2018;10(1):55
PMID: 30029672 (Weblink)

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J.
Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138.
PMID: 18927285 (Weblink)

Pancreatic ductal adenocarcinoma (PDAC) PDX models

Establishment and thorough characterization of pancreatic cancer patient derived xenograft (PDX) models for molecular analyses and chemosensitivity testing.
Behrens D, Pfohl U, Dahlmann M, Conrad T, Becker M, Brzezicha B, Büttner B, Wagner S, Hallas C, Lawlor R, Khazak V, Linnebacher M, Wartmann T, Fichtner I, Hoffmann J, Walther W. Cancers, 2023, 15(24):5753.
PMID: 38136299  (Weblink)

Effective Oncoleaking Treatment of Pancreatic Cancer by Claudin-Targeted Suicide Gene Therapy with Clostridium perfringens Enterotoxin (CPE).
Pahle J, Kobelt D, Aumann J, Behrens D, Daberkow O, Mokritzkij M, Piontek J, Stein U, Walther W.
Cancers (Basel). 2021 Aug 31;13(17):4393. doi: 10.3390/cancers13174393.
PMID: 34503203 (Weblink)

Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology.
Osuna de la Peña D, Trabulo SMD, Collin E, Liu Y, Sharma S, Tatari M, Behrens D, Erkan M, Lawlor RT, Scarpa A, Heeschen C, Mata A, Loessner D. Nat Commun. 2021;12(1):5623 doi: 10.1038/s41467-021-25921-9.
PMID: 34561461 (Weblink)

Pancreatic cancer models for translational research.
Behrens D, Walther W, Fichtner I. Pharmacol Ther. 2017 May;173:146-158. doi: 10.1016/j.pharmthera.2017.02.013.Epub 2017 Feb 4.
PMID: 28174092 (Weblink)

Renal cancer PDX models

A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies.
Gürgen D, Becker M, Dahlmann M, Flechsig S, Schaeffeler E, Büttner FA, Schmees C, Bohnert R, Bedke J, Schwab M, Wendler JJ, Schostak M, Jandrig B, Walther W, Hoffmann Front Oncol. 2022;
12:889789. doi: 10.3389/fonc.2022.889789
PMID: 35800063 (Weblink)

    Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients
    Annika Fendler, Daniel Bauer, Jonas Busch, Klaus Jung, Annika Wulf-Goldenberg, Severine Kunz, Kun Song, Adam Myszczyszyn, Sefer Elezkurtaj, Bettina Erguen, Simone Jung, Wei Chen, Walter Birchmeier
    Nat Commun. 2020; 11: 929. Published online 2020 Feb 17. doi: 10.1038/s41467-020-14700-7
    PMID: 33349639 (Weblink)

    Melanoma PDX models

    Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector.
    Kobelt D, Aumann J, Schmidt M, Wittig B, Fichtner I, Behrens D, Lemm M, Freundt G, Schlag PM, Walther W.
    Mol Oncol. 2014 May;8(3):609-19. doi: 10.1016/j.molonc.2013.12.019. Epub 2014 Jan 18.
    PMID: 24503218 (Weblink)

    Glioblastoma PDX models

    Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures. Alcaniz J, Winkler L, Dahlmann M, Becker M,Orthmann A, Heybaeck J, Krassnig S, Skofler C, Kratzsch T, Kuhn SA, Jödicke A, Linnebacher M, Fichtner I, Walther W, Hoffmann J. Front Oncol, 2023; 13: 1129627,
    PMID 37114125(Weblink)

    Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas. Kratzsch T, Kuhn SA, Joedicke A, Hanisch UK, Vajkoczy P, Hoffmann J, Fichtner I. J Cancer
    Res Clin Oncol. 2018;144(5):809-819
    PMID: 29427211(Weblink)

      Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies.
      William D, Mullins CS, Schneider B, Orthmann A, Lamp N, Krohn M, Hoffmann A, Classen CF, Linnebacher M. J Transl
      Med. 2017;15(1):27 
      PMID: 28183348 (Weblink)

      Pediatric Cancers PDX models

      Therapeutic targeting of ATR in alveolar rhabdomyosarcoma.
      Dorado García H, Pusch F, Bei Y, von Stebut J, Ibáñez G, Guillan K, Imami K, Gürgen D, Rolff J, Helmsauer K, Meyer-Liesener S, Timme N, Bardinet V, Chamorro González R, MacArthur IC, Chen CY, Schulz J, Wengner AM, Furth C, Lala B, Eggert A, Seifert G, Hundsoerfer P, Kirchner M, Mertins P, Selbach M, Lissat A, Dubois F, Horst D, Schulte JH, Spuler S, You D, Dela Cruz F, Kung AL, Haase K, DiVirgilio M, Scheer M, Ortiz MV, Henssen AG.
      Nat Commun. 2022, 13(1):4297
      PMID: 35879366 (Weblink)

      Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions. Schmelz K, Toedling J, Huska M, Cwikla MC, Kruetzfeldt LM, Proba J, Ambros PF, Ambros IM, Boral S, Lodrini M, Chen CY, Burkert M, Guergen D, Szymansky A, Astrahantseff K, Kuenkele A, Haase K, Fischer M, Deubzer HE, Hertwig F, Hundsdoerfer P, Henssen AG, Schwarz RF, Schulte JH, Eggert A.
      Nat Commun. 2021 Nov 23;12(1):6804.
      PMID: 34815394 (Weblink)

        Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma. Arlt B, Zasada C, Baum K, Wuenschel J, Mastrobuoni G, Lodrini M, Astrahantseff K, Winkler A, Schulte JH, Finkler S, Forbes M, Hundsdörfer P, Gürgen D, Hoffmann J, Wolf J, Eggert A, Kempa S, Deubzer HE.
        Int J Cancer. 2021;148(5):1219-1232
        PMID: 33284994 (Weblink)

          Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors.
          Timme N, Han Y, Liu S, Yosief HO, Garcıa HD, Bei Y, Klironomos F, MacArthur IC, Szymansky A, von Stebut J, Bardinet V, Dohna C, Künkele A, Rolff J, Hundsdörfer P, Lissat A, Seifert G, Eggert A, Schulte JH, Zhang W, Henssen AG.
          Transl Oncol 2020; 13: 221-232
          PMID: 31869746 (Weblink)

            Breast cancer models PDX models

            Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline.
            MaCa 3366/TAM. Becker M, Sommer A, Krätzschmar JR, Seidel H, Pohlenz HD, Fichtner I.
            Mol Cancer Ther. 2005 Jan;4(1):151-68
            PMID: 15657362 (Weblink)

              Metastasis models

              Patient-Derived Xenografts from Solid Tumors (PDX) for Models of Metastasis.
              Wulf-Goldenberg A, Hoffmann J, Becker M, Brzezicha B, Walther W              .
              Methods Mol Biol. 2021;2294:43-58. doi: 10.1007/978-1-0716-1350-4_4,
              PMID: 33742393 (Weblink)

                Targeted delivery of CCR2 antagonist to activated pulmonary endothelium prevents metastasis.
                Roblek M, Calin M, Schlesinger M, Stan D, Zeisig R, Simionescu M, Bendas G, Borsig L. 
                J Control Release. 2015; 220(Pt A):341-347
                PMID: 26522070 (Weblink)

                  Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRP-targeting on the therapeutic result. Orthmann A, Zeisig R, Süss R, Lorenz D, Lemm M, Fichtner I.
                  Pharm Res. 2012; 29(7):1949-59
                  PMID: 22399388 (Weblink)

                    Inhibition of pulmonary metastasis in a human MT3 breast cancer xenograft model by dual liposomes preventing intravasal fibrin clot formation.
                    Wenzel J, Zeisig R, Haider W, Habedank S, Fichtner I.
                    Breast Cancer Res Treat. 2010; 121(1):13-22
                    PMID: 19548083 (Weblink)

                      Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.
                      Hoffmann J, Fichtner I, Lemm M, Lienau P, Hess-Stumpp H, Rotgeri A, Hofmann B, Klar U.
                      Neuro Oncol. 2009; 11(2):158-66
                      PMID: 18780814 (Weblink)

                        2024

                        Broadening the Scope of Sapofection: Cationic Peptide-Saponin Conjugates Improve Gene Delivery In Vitro and In Vivo.
                        Kolster M, Sonntag A, Weise C, Correa J, Fuchs H, Walther W, Fernandez-Megia E, Weng A. ACS Appl Mater Interfaces.
                        2024 Jul 17;16(28):36095-36105.
                        PMID: 38970470 (Weblink)

                        Passenger gene co-amplifications create collateral therapeutic vulnerabilities in cancer. 
                        Bei Y, Brame L, Kirchner M, Fritsche-Guenther R, Kunz S, Bhattacharya A, Rusu MC, Gürgen D, Dubois FPB, Koppke JKC, Proba J, Wittstruck N, Sidorova OA, Chamorro Gonzalez R, Dorado Garcia H, Bruckner L, Xu R, Giurgiu M, Rodriguez-Fos E, Yu Q, Spanjaard B, Koche RP, Schmitt CA, Schulte JH, Eggert A, Haase K, Kirwan J, Hagemann AI, Mertins P, Dorr JR, Henssen AG. Cancer Discov.
                        2024 Mar 1;14(3):492-507. doi: 10.1158/2159-8290.CD-23-1189
                        PMID: 38197697 (Weblink)

                        EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models.
                        Sagini MN, Zepp M, Eyol E, Ali DM, Gromova S, Dahlmann M, Behrens D, Groeschel C, Tischmeier L, Hoffmann J, Berger MR, Forssmann WG. Peptides.
                        2024 May:175:171111. doi: 10.1016/j.peptides.2023.171111.
                        PMID: 38036098 (Weblink)

                        Activation of gp130 signaling in T cells drives TH17-mediated multi-organ autoimmunity.
                        Baumgartner F, Bamopoulos SA, Faletti L, Hsiao HJ, Holz M, Gonzalez-Menendez I, Boldo L, Horne A, Gosavi S, Özerdem C, Singh N, Liebig S, Ramamoorthy S, Lehmann M, Demel U, Kühl AA, Wartewig T, Ruland J, Wunderlich FT, Schick M, Walther W, Rose-John S, Haas S, Quintanilla-Martinez L, Feske S, Ehl S, Glauben R, Keller U. Sci Signal.
                        2024; Feb 20;17(824):eadc9662. doi: 10.1126/scisignal.adc9662
                        PMID: 38377177 (Weblink)

                        Integration of ζ-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cells.
                        Kath J, Franke C, Drosdek V, Du W, Glaser V, Fuster-Garcia C, Stein M, Zittel T, Schulenberg S, Porter CE, Andersch L, Künkele A, Alcaniz J, Hoffmann J, Abken H, Abou-El-Enein M, Pruß A, Suzuki M, Cathomen T, Stripecke R, Volk HD, Reinke P, Schmueck-Henneresse M, Wagner DL. Blood.
                        2024 Mar 17:blood.2023020973
                        PMID: 38493479 (Weblink)

                        Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation.
                        Godfrey LK, Forster J, Liffers ST, Schröder C, Köster J, Henschel L, Ludwig KU, Lähnemann D, Trajkovic-Arsic M, Behrens D, Scarpa A, Lawlor RT, Witzke KE, Sitek B, Johnsen SA, Rahmann S, Horsthemke B, Zeschnigk M, Siveke JT. Clin Epigenetics.
                        2024 Jan 16;16(1):13. doi: 10.1186/s13148-024-01623-z.
                        PMID: 38229153 (Weblink)


                        2023

                        A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer
                        Sandra Kendzia, Susanne Franke, Tarek Kröhler, Nicole Golob-Schwarzl, Caroline Schweiger, Anna M. Toeglhofer, Christina Skofler, Stefan Uranitsch, Amin El-Heliebi, Julia Fuchs, Andreas Punschart, Philipp Stiegler, Marlen Keil, Jens Hoffmann, David Henderson, Hans Lehrach, Marie-Laure Yaspo, Christoph Reinhard, Reinhold Schäfer, Ulrich Keilholz, Christian Regenbrecht, Rudolf Schicho, Peter Fickert, Sigurd F. Lax, Frank Erdmann, Marcel H. Schulz, Alexandra K. Kiemer, Johannes Haybaeck & Sonja M. Kessler, Published: 30 May 2023, Mol Cancer, 2023;22:89
                        PMID: 37248468  (Weblink)

                        The Chorioallantoic Membrane Xenograft Assay as a Reliable Model for Investigating the Biology of Breast Cancer
                        Ranjan RA, Muenzner JK, Kunze P, Geppert CI, Ruebner M, Huebner H, Fasching PA, Beckmann MW, Bäuerle T, Hartmann A, Walther W, Eckstein M, Erber R, Schneider-Stock R. Cancers (Basel). 2023, 10;15(6):1704
                        PMID 36980588  (Weblink)

                        Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance
                        Danielli SG, Porpiglia E, De Micheli AJ, Navarro N, Zellinger MJ, Bechtold I, Kisele S, Volken L, Marques JG, Kasper S, Bode PK, Henssen AG, Gürgen D,Delattre O, Surdez D, Roma J, Bühlmann P, Blau HM, Wachtel M, Schäfer BW.  Sci Adv. 2023 Feb 10;9(6):eade9238,
                        PMID 36753540  (Weblink)

                        Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
                        Grünewald S, Stecklum M, Rizzo M, Rathjens J, Fiebig L, Zopf D. Eur J Med Res, 2023; 28: 147,
                        PMID 37013652  (Weblink)


                        2022

                        Rapid testing of candidate oncogenes and tumour suppressor genes in signal transduction and neoplastic transformation.
                        Liu S, Medina-Perez P, Ha-Thi MC, Wieland A, Stecklum M, Hoffmann J, Tchernitsa O, Sers C, Schäfer R.
                        Adv Biol Regul. 2022;83:100841 (Weblink)

                        Prädiktive Testung von Tumorgewebe und ihre klinischen Konsequenzen.
                        Hoffmann J.In: Schmoll HJ. (eds) Kompendium Internistische Onkologie. 2022, Springer Reference Medizin. Springer, Berlin, Heidelberg. (Weblink)

                        Radiofrequency Electromagnetic Fields Cause Non-Temperature-Induced Physical and Biological Effects in Cancer Cells.
                        Wust P, Veltsista PD, Oberacker E, Yavvari P, Walther W, Bengtsson O, Sterner-Kock A, Weinhart M, Heyd F, Grabowski P, Stintzing S, Heinrich W, Stein U, Ghadjar P. 
                        Cancers (Basel). 2022, 14(21):5349 (Weblink)

                        Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors.
                        Heynen GJJE, Lisek K, Vogel R, Wulf-Goldenberg A, Alcaniz J, Montaudon E, Marangoni E, Birchmeier W. Breast
                        Cancer Res. 2022;24(1):23 (Weblink)

                        Calcium-binding protein S100P is a new target gene of MACC1, drives colorectal cancer metastasis and serves as a prognostic biomarker.
                        Schmid F, Dahlmann M, Röhrich H, Kobelt D, Hoffmann J, Burock S, Walther W, Stein U.
                        Br J Cancer. 2022; 127(4):675-685 (Weblink)

                        Real-world evidence for preventive effects of statins on cancer incidence: A trans-Atlantic analysis.
                        Gohlke BO, Zincke F, Eckert A, Kobelt D, Preissner S, Liebeskind JM, Gunkel N, Putzker K, Lewis J, Preissner S, Kortüm B, Walther W, Mura C, Bourne PE, Stein U, Preissner R.
                        Clin Transl Med. 2022; 12(2):e726, (Weblink)

                        Conventional amphotericin B elicits markers of immunogenic cell death in leukemic blasts, mediates immunostimulatory effects in phagocytic cells, and synergizes with PD-L1 blockade.
                        Kofla G, Radecke C, Frentsch M, Walther W, Stintzing S, Riess H, Bullinger L,
                        I-K Na. Oncoimmunology, 2022; 11: 2068109, (Weblink)

                        Inhibition of MACC1-Induced Metastasis in Esophageal and Gastric Adenocarcinomas.
                        Treese C, Werchan J, von Winterfeld M, Berg E, Hummel M, Timm L, Rau B, Daberkow O, Walther W, Daum S, Kobelt D, Stein U. Cancers (Basel), 2022; 14: 1773 (Weblink)

                        Marker and Potential Therapeutic Target in Adenocarcinoma of the Stomach and Esophagus.
                        Treese C, Hartl K, Pötzsch M, Dahlmann M, von Winterfeld M, Berg E, Hummel M, Timm L, Rau B, Walther W, Daum S, Kobelt D, Stein U. Cells, 2022; 11: 1056 (Weblink)

                        Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.
                        Ng YLD, Ramberger E, Bohl SR, Dolnik A, Steinebach C, Conrad T, Müller S, Popp O, Kull M, Haji M, Gütschow M, Döhner H, Walther W, Keller U, Bullinger L, Mertins P, Krönke J.
                        Nat Commun, 2022; 13: 1009, (Weblink)

                        Suicide nanoplasmids coding for ribosome-inactivating proteins.
                        Mitdank H, Tröger M, Sonntag A, Shirazi NA, Woith E, Fuchs H, Kobelt D, Walther W, Weng A. Eur J Pharm Sci,
                        2022; 170:106107 (Weblink)


                        2021

                        M01 as a novel drug enhancer for specifically targeting the blood-brain barrier.
                        Breitkreuz-Korff O, Tscheik C, Del Vecchio G, Dithmer S, Walther W, Orthmann A, Wolburg H, Haseloff RF, Schröder L, Blasig IE, Winkler L. J Control Release,
                        2021; 338: 137-148, (Weblink)

                        CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus.
                        Textor A, Grunewald L, Anders K, Klaus A, Schwiebert S, Winkler A, Stecklum M, Rolff J, Henssen AG, Höpken UE, Eggert A, Schulte JH, Jensen MC, Blankenstein T, Künkele A.. Cancers (Basel). 2021;13(5):1050 (Weblink)


                        2020

                        Pre-operative cellular dissociation grading in biopsies is highly predictive of post-operative tumour stage and patient outcome in head and neck squamous cell carcinoma.
                        Jesinghaus M, Steiger K, Stögbauer F, Haller B, Kolk A, Straßen U, Pickhard A, Wirth M, Silva M, Budczies J, Becker von Rose A, Konukiewitz B, Kuhn P, Klinghammer K, Dapper H, Münch S, Combs SE, Weichert W, Boxberg M.
                        Br J Cancer 2020; 122: 835-846, (Weblink)

                        Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC
                        Messerschmidt C, Obermayer B, Klinghammer K, Ochsenreither S, Treue D, Stenzinger A, Glimm H, Fröhling C, Kindler T, Brandts CH, Schulze-Osthoff K, Weichert W, Tinhofer I, Klauschen F, Keilholz U, Beule D, Rieke DT.
                        Int J Cancer 2020; 147: 2293-2302 (Weblink)

                        In-vitro and in-vivo investigations into the carbene-gold anticancer drug candidates NHC*-Au-SCSNMe2 and NHC*-Au-S-GLUC against advanced prostate cancer PC3.
                        Walther W,                         Althagafi D, Curran D, O’Beirne C, Mc Carthy C, Ott I, Tacke M.
                        Anti-Cancer Drugs 2020, 31(7), 672-683, (Weblink)

                        Targeting claudin-overexpressing thyroid and lung cancer by modified Clostridium perfringens enterotoxin.
                        Piontek A, Eichner M, Zwanziger D, Beier LS, Protze J, Walther W, Theurer S, Schmid WK, Fuhrer-Sakel D, Piontek J, Krause G.
                        Mol Oncol 2020; 14: 261-276 (Weblink)

                        TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer.
                        Zhao B, Dierichs L, Gu JN, Trajkovic-Arsic M, Hilger RA, Savvatakis K, Vega-Rubin-de-Celis S, Liffers ST, Peña-Llopis S, Behrens D, Hahn, Siveke JT, Lueong SS.
                        Cell Death Discov 2020; 6 (Weblink)


                        2019

                        A new device to prevent fascial retraction in the open abdomen - proof of concept in vivo.
                        Eickhoff R, Guschlbauer M, Maul AC, Klink CD, Neumann UP, Engel M, Hellmich M, Sterner-Kock A, Krieglstein CF.
                        BMC Surg. 2019;19(1):82 (Weblink)

                        Human melanoma brain metastases cell line MUG-Mel1, isolated clones and their detailed characterization.
                        Heitzer E, Groenewoud A, Meditz K, Lohberger B, Liegl-Atzwanger B, Prokesch A, Kashofer K, Behrens D, Haybaeck J, Kolb-Lenz D, Koefeler H, Riedl S, Schaider H, Fischer C, Snaar-Jagalska BE, de'Jong D, Szuhai K, Zweytick D, Rinner B.
                        Sci Rep. 2019;9(1):4096 (Weblink)

                        A synthetic epoxyeicosatrienoic acid analogue prevents the initiation of ischemic acute kidney injury.
                        Hoff U, Bubalo G, Fechner M, Blum M, Zhu Y, Pohlmann A, Hentschel J, Arakelyan K, Seeliger E, Flemming B, Gürgen D, Rothe M, Niendorf T, Manthati VL, Falck JR, Haase M, Schunck WH, Dragun D.
                        Acta Physiol (Oxf). 2019;227(2):e13297 (Weblink)

                        Prohibitin promotes de-differentiation and is a potential therapeutic target in neuroblastoma.
                        MacArthur IC, Bei Y, Garcia HD, Ortiz MV, Toedling J, Klironomos F, Rolff J, Eggert A, Schulte JH, Kentsis A,
                        Henssen AG. JCI Insight. 2019;5(10):e127130 (Weblink)

                        RPL22L1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance.
                        Rao S, Peri S, Hoffmann J, Cai KQ, Harris B, Rhodes M, Connolly DC, Testa JR,
                        Wiest DL. PLoS One. 2019;14(10):e0222392 (Weblink)

                        mTORC1 and mTORC2 Differentially Regulate Cell Fate Programs to Coordinate Osteoblastic Differentiation in Mesenchymal Stromal Cells.
                        Schaub T, Gürgen D, Maus D, Lange C, Tarabykin V, Dragun D, Hegner B.
                        Sci Rep. 2019 Dec 27;9(1):20071 (Weblink)

                        Esophageal Heat Exchanger Versus Water-Circulating Cooling Blanket for Targeted Temperature Management.
                        Schroeder DC, Maul AC, Guschlbauer M, Finke SR, de la Puente Bethencourt D, Neumann T, Padosch SA, Annecke T, Böttiger BW, Sterner-Kock A, Herff H.
                        Ther Hypothermia Temp Manag. 2019;9(4):251-257 (Weblink)

                        Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures.
                        Schumacher D, Andrieux G, Boehnke K, Keil M, Silvestri A, Silvestrov M, Keilholz U, Haybaeck J, Erdmann G, Sachse C, Templin M, Hoffmann J, Boerries M, Schäfer R, Regenbrecht CRA.
                        PLoS Genet. 2019 Mar 29;15(3):e1008076 (Weblink)

                        MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.
                        Schwarzenbacher D, Klec C, Pasculli B, Cerk S, Rinner B, Karbiener M, Ivan C, Barbano R, Ling H, Wulf-Goldenberg A, Stanzer S, Rinnerthaler G, Stoeger H, Bauernhofer T, Haybaeck J, Hoefler G, Jahn SW, Parrella P, Calin GA, Pichler M.
                        Breast Cancer Res. 2019;21(1):20 (Weblink)

                        The Wnt-Driven Mll1 Epigenome Regulates Salivary Gland and Head and Neck Cancer.
                        Zhu Q, Fang L, Heuberger J, Kranz A, Schipper J, Scheckenbach K, Vidal RO, Sunaga-Franze DY, Müller M, Wulf-Goldenberg A, Sauer S, Birchmeier W.
                        Cell Rep. 2019;26(2):415-428, (Weblink)


                        2018

                        Editorial: Cancer Models.
                        Breitenbach M, Hoffmann J. Front Oncol. 2018;8:40, (Weblink)

                        Loss-of-function uORF mutations in human malignancies.
                        Schulz J, Mah N, Neuenschwander M, Kischka T, Ratei R, Schlag PM, Castaños-Vélez E, Fichtner I, Tunn PU, Denkert C, Klaas O, Berdel WE, von Kries JP, Makalowski W, Andrade-Navarro MA, Leutz A, Wethmar K.
                        Sci Rep. 2018; 8(1):2395, (Weblink)

                        Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.
                        Piggott L, Silva A, Robinson T, Santiago-Gómez A, Simões BM, Becker M, Fichtner I, Andera L, Young P, Morris C, Barrett-Lee P, Alchami F, Piva M, Vivanco MD, Clarke RB, Gee J, Clarkson R.
                        Clin Cancer Res. 2018; 24(10):2452-2463, (Weblink)

                        Targeted suicide gene transfections reveal promising results in nu/nu mice with aggressive neuroblastoma.
                        Sama S, Woith E, Walther W, Jerz G, Chen W, Hart S, Melzig MF, Weng A.
                        J Control Release. 2018; 275:208-216, (Weblink)

                        Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors.
                        Briest F, Grass I, Sedding D, Möbs M, Christen F, Benecke J, Fuchs K, Mende S, Kaemmerer D, Sänger J, Kunze A, Geisler C, Freitag H, Lewens F, Worpenberg L, Iwaszkiewicz S, Siegmund B, Walther W, Hummel M, Grabowski P.
                        Neuroendocrinology. 2018; 107(1):1-23, (Weblink)

                        Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors.
                        Holstein M, Mesa-Nuñez C, Miskey C, Almarza E, Poletti V, Schmeer M, Grueso E, Ordóñez Flores JC, Kobelt D, Walther W, Aneja MK, Geiger J, Bonig HB, Izsvák Z, Schleef M, Rudolph C, Mavilio F, Bueren JA, Guenechea G, Ivics Z.
                        Mol Ther. 2018;26(4):1137-1153, (Weblink)


                        2017

                        miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5.
                        Stiegelbauer V, Vychytilova-Faltejskova P, Karbiener M, Pehserl AM, Reicher A, Resel M, Heitzer E, Ivan C, Bullock M, Ling H, Deutsch A, Wulf-Goldenberg A, Adiprasito JB, Stoeger H, Haybaeck J, Svoboda M, Stotz M, Hoefler G, Slaby O, Calin GA, Gerger A, Pichler M.
                        Clin Cancer Res 2017; 23(17):5255-5266, (Weblink)

                        Implementing liquid biopsies into clinical decision making for cancer immunotherapy.
                        Quandt D, Zucht HD, Amann A, Wulf-Goldenberg A, Borrebaeck C, Cannarile M, Lambrechts D, Herbert Oberacher H, Garrett J, Nayak T, Kazinski M, Massie C, Schwarzenbach H, Maio M, Prins R, Wendik B, Hockett R, Enderle D, Noerholm M, Hendriks H, Zwierzina H, Seliger B.
                        Oncotarget 2017; 8:48507-20, (Weblink)

                        Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.
                        Schütte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D, Keil M, Yildiriman R, Jandrasits C, Borodina T, Amstislavskiy V, Worth CL, Schweiger C, Liebs S, Lange M, Warnatz HJ, Butcher LM, Barrett JE, Sultan M, Wierling C, Golob-Schwarzl N, Lax S, Uranitsch S, Becker M, Welte Y, Regan JL, Silvestrov M, Kehler I, Fusi A, Kessler T, Herwig R, Landegren U, Wienke D, Nilsson M, Velasco JA, Garin-Chesa P, Reinhard C, Beck S, Schäfer R, Regenbrecht CR, Henderson D, Lange B, Haybaeck J, Keilholz U, Hoffmann J, Lehrach H, Yaspo ML.
                        Nat Commun. 2017; 8:14262, (Weblink)

                        Cancer Stem Cells Regulate Cancer-Associated Fibroblasts via Activation of Hedgehog Signaling in Mammary Gland Tumors.
                        Valenti G, Quinn HM, Heynen GJJE, Lan L, Holland JD, Vogel R, Wulf-Goldenberg A, Birchmeier W.
                        Cancer Res. 2017; 77(8):2134-2147, (Weblink)


                        2016

                        Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis.
                        Pichler M, Stiegelbauer V, Vychytilova-Faltejskova P, Ivan C, Ling H, Winter E, Zhang X, Goblirsch M, Wulf-Goldenberg A, Ohtsuka M, Haybaeck J, Svoboda M, Okugawa Y, Gerger A, Hoefler G, Goel A, Slaby O, Calin GA.
                        Clin Cancer Res. 2017; 23(5):1323-1333 (Weblink)

                        Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.
                        Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R, Andrianov G, Bobrov E, Lysenko E, Skobeleva N, Gabitova L, Restifo D, Pressman M, Serebriiskii IG, Hoffman JP, Paz K, Behrens D, Khazak V, Jablonski SA, Golemis EA, Weiner LM, Astsaturov I.
                        Clin Cancer Res. 2016; 22(24):6153-6163 (Weblink)

                        Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts.
                        Rolff J, Becker M                        , Merk J, Hoffmann J, Fichtner I.
                        Target Oncol. 2016; 11(4):507-14 (Weblink)

                        Improved treatment of MT-3 breast cancer and brain metastases in a mouse xenograft by LRP-targeted oxaliplatin liposomes.
                        Orthmann A, Peiker L, Fichtner I, Hoffmann A, Hilger RA, Zeisig R. J
                        Biomed Nanotechnol 2016; 12: 56-68 (Weblink)

                        A Small-Molecule Antagonist of the β-Catenin/TCF4 Interaction Blocks the Self-Renewal of Cancer Stem Cells and Suppresses Tumorigenesis.
                        Fang L, Zhu Q, Neuenschwander M, Specker E, Wulf-Goldenberg A, Weis WI, von Kries JP, Birchmeier W.
                        Cancer Res. 2016 Feb 15;76(4):891-901 (Weblink)

                        SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient survival.
                        Schmid F, Wang Q, Huska MR, Andrade-Navarro MA, Lemm M, Fichtner I, Dahlmann M, Kobelt D, Walther W, Smith J, Schlag PM, Stein U. Oncogene. 2016; 35(46):5942-5952 (Weblink)


                        2015

                        Predictive in vivo models for oncology.
                        Behrens D, Rolff J, Hoffmann J.                         Handb Exp Pharmacol.
                        2015 (Weblink)

                        Periodic harvesting of embryonic stem cells from a hollow-fiber membrane based four-compartment bioreactor.
                        Knöspel F, Freyer N, Stecklum M, Gerlach JC, Zeilinger K.
                        Biotechnol Prog. 2016;32(1):141-51 (Weblink)

                        New Wnt/β-catenin target genes promote experimental metastasis and migration of colorectal cancer cells through different signals.
                        Qi J, Yu Y, Akilli Öztürk Ö, Holland JD, Besser D, Fritzmann J, Wulf-Goldenberg A, Eckert K, Fichtner I, Birchmeier W.
                        Gut 2015; 65(10):1690-701 (Weblink)

                        Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo.
                        Gajer JM, Furdas SD, Gründer A, Gothwal M, Heinicke U, Keller K, Colland F, Fulda S, Pahl HL, Fichtner I, Sippl W, Jung M.
                        Oncogenesis 2015; 4(2): e 137 (Weblink)

                        How perifosine affects liposome-encapsulated drug delivery across a cell barrier
                        Testen A, Podlipec R, Mravljak J, Orthmann A, Šentjurc M, Zeisig R, Štrancar J, Koklic T.
                        Therapeutic Delivery 2015; 6(4), 423-441 (Weblink)

                        Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice.
                        Lan L, Holland JD, Qi J, Grosskopf S, Rademann J, Vogel R, Györffy B, Wulf-Goldenberg A, Birchmeier W.
                        The EMBO Journal 2015; 34(11), 1493-508 (Weblink)

                        Cell differentiation mediated by co-culture of human umbilical cord blood stem cells with murine hepatic cells.
                        Stecklum M, Wulf-Goldenberg A, Purfürst B, Siegert A, Keil M, Eckert K, Fichtner I.
                        In Vitro Cellular & Developmental Biology Animal 2015; 51(2), 183-191 (Weblink)

                        Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.
                        Weilemann A, Grau M, Erdmann T, Merkel O, Sobhiafshar U, Anagnostopoulos I, Hummel M, Siegert A, Hayford C, Madle H, Wollert-Wulf B, Fichtner I, Dörken B, Dirnhofer S, Mathas S, Janz M, Emre NC, Rosenwald A, Ott G, Lenz P, Tzankov A, Lenz G.
                        Blood 2015; 125(1), 124-132 (Weblink)